On Oct. 12, 2021, National Resilience announced a strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to implement…
On Oct. 11, 2021, Merck and Ridgeback Biotherapeutics announced that Merck had submitted an Emergency Use Authorization (EUA)…
On Oct. 11, 2021, scientists at Washington University School of Medicine in St. Louis announced they had developed…
On Oct. 11, 2021, Inovio Pharmaceuticals announced that it had received authorization from Colombia’s INVIMA, to conduct the…
On Oct. 7, 2021, the Centers for Disease Control and Prevention (CDC) reported One U.S. child loses a…
On Oct. 6, 2021, the U.S. Department of Agriculture’s Agriculture Research Service (ARS) announced confirmation of SARS-CoV-2 (the…
On Oct. 6, 2021, Vaxart announced that it had begun recruiting subjects for its Phase II COVID-19 oral…
On Oct. 6, 2021, AIM ImmunoTech released detailed safety data from a Phase 1 clinical study which supported…
On Oct. 6, 2021, Washington University School of Medicine announced the start of a pediatric COVID-19 vaccine clinical…
On Oct. 5, 2021, PerkinElmer announced that the U.S. Food and Drug Administration had provided Emergency Use Authorization…
On Oct. 5, 2021, Moderna announced that the European Medicines Agency (EMA) had authorized a third dose of…
On Oct. 5, 2021, Johnson & Johnson announced it had submitted data to the U.S. Food and Drug…
On Oct. 5, 2021, a new report from the U.S. Department of Health and Human Services (HHS) showed…
On Oct. 4, 2021, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
On Oct. 4, 2021, ACON Laboratories announced that its Flowflexï¾™ COVID-19 Antigen Home Test had been authorized for…
On Oct. 1, 2021, Merck and Ridgeback Biotherapeutics announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine,…
On Oct. 1, 2021, Humanigen announced it had submitted all the planned modules as well as a risk…
On Oct. 1, 2021, LabCorp announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
On Sept. 30, 2021, RELIEF THERAPEUTICS reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals,…
On Sept. 30, 2021, the WHO announced that fifteen African countries – nearly a third of the continent’s…
On Sept. 30, 2021, Trevena announced data from 30 patients enrolled in the proof-of-concept study of TRV027, the…
This cartoon illustrates the various issues facing individuals across the U.S. who are vaccinated against COVID-19 verus those…
On Sept. 29, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…
On Sept. 29, 2021, Regeneron announced that the New England Journal of Medicine (NEJM) published positive detailed results…
On Sept. 29, 2021, VBI Vaccines announced positive results from multiple preclinical studies against several COVID-19 variants of…
On Sept. 29, 2021, Roche confirmed positive data from the phase II/III 2066 study, investigating Ronapreveï¾™ (casirivimab and…
On Sept. 29, 2021, the University of Pennsylvania announced that the Breakthrough Prize in Life Sciences was awarded…
On Sept. 29, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
On Sept. 28, 2021, Sanofi announced that it had terminated plans for its own mRNA-based COVID-19 vaccine given…
On Sept. 28, 2021, AIM ImmunoTech announced that is had submitted a Pre-Investigational New Drug application (Pre-IND) to…